Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application

Journal of Cataract and Refractive Surgery

Volumn 37, Issue 6, 2011, Pages 1082-1089

  Donnenfeld, Eric D ^a   Comstock, Timothy L ^a   Proksch, Joel W ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BESIFLOXACIN; CIPROFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN;

ADULT; AQUEOUS HUMOR; ARTICLE; DRUG CONCENTRATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENDOPHTHALMITIS; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS EPIDERMIDIS; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; AZEPINES; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; QUINOLINES; TANDEM MASS SPECTROMETRY;

EID: 79956218074     PISSN: 08863350     EISSN: 18734502     Source Type: Journal    
DOI: 10.1016/j.jcrs.2010.12.046     Document Type: Article

References (49)

1. Flynn HW Jr, Scott IU, Brod RD, Han DP. Current management of endophthalmitis. Int Ophthalmol Clin 2004; 44:115-137 (Pubitemid 39392082)
2. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991; 98:639-649; discussion by J Baum, 650
3. Bannerman TL, Rhoden DL, McAllister SK, Miller JM, Wilson LA for the Endophthalmitis Vitrectomy Study Group. The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study; a comparison of eyelid and intraocular isolates using pulsed-field electrophoresis. Arch Ophthalmol 1997; 115:357-361. Available at: http://archopht.ama-assn.org/cgi/reprint/115/3/ 357.pdf. Accessed February 5, 2011
4. Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol 2004; 137:38-42 (Pubitemid 38045185)
5. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study; the Endophthalmitis Vitrectomy Study Group. Am J Ophthalmol 1996; 122:1-17; correction, 920
6. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery; an evidence-based update. Ophthalmology 2002; 109:13-26
7. Lalwani GA, Flynn HW Jr, Scott IU, Quinn CM, Berrocal AM, Davis JL, Murray TG, Smiddy WE, Miller D. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005); clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 2008; 115:473-476
8. Moshirfar M, Feiz V, Vitale AT, Wegelin JA, Basavanthappa S, Wolsey DH. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones; a retrospective observational case series. Ophthalmology 2007; 114:686-691 (Pubitemid 46483686)
9. Wu P-C, Kuo H-K, Li M, Lai I-C, Fang P-C, Lin S-A, Shin S-J, Chen Y-J, Teng M-C. Nosocomial postoperative endophthalmitis: a 14-year review. Graefes Arch Clin Exp Ophthalmol 2006; 244:920-929 (Pubitemid 44184495)
10. Barry P, Seal DV, Gettinby G, Lees F, Peterson M, Revie CW for the ESCRS Endophthalmitis Study Group. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery; preliminary report of principal results from a European multicenter study. J Cataract Refract Surg 2006; 32:407-410 (Pubitemid 44313820)
11. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007; 33:978-988
12. Ta CN, Chan I, Dhatt HS, Paterno J, Fisher E, Singh K, Montague A, Egbert PR, Cockerham G, Mino De Kaspar H. Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application. J Ocul Pharmacol Ther 2008; 24:427-431
13. Miño de Kaspar H, Kreutzer TC, Aguirre-Romo I, Ta CN, Dudichum J, Bayrhof M, Klauss V, Kampik A. A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Am J Ophthalmol 2008; 145:136-142
14. Jensen MK, Fiscella RG, Moshirfar M, Mooney B. Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years. J Cataract Refract Surg 2008; 34:1460-1467
15. Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006; 124:479-483. Available at: http://archopht.ama-assn.org/cgi/ reprint/124/4/479.pdf. Accessed February 5, 2011
16. Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 2006; 142:721-725
17. Deramo VA, Lai JC, Winokur J, Luchs J, Udell IJ. Visual outcome and bacterial sensitivity after methicillin-resistant Staphylococcus aureus-associated acute endophthalmitis. Am J Ophthalmol 2008; 145:413-417
18. Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch Ophthalmol 2005; 123:341-346. Available at: http://archopht.ama-assn.org/cgi/ reprint/123/3/341.pdf. Accessed February 5, 2011 (Pubitemid 41007578)
19. Harper T, Miller D, Flynn HW Jr. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative Staphylococcus endophthalmitis isolates. Ophthalmology 2007; 114:871-875
20. Major JC Jr, Engelbert M, Flynn HW Jr, Miller D, Smiddy WE, Davis JL. Staphylococcus aureus endophthalmitis: antibiotic susceptibilities, methicillin resistance, and clinical outcomes. Am J Ophthalmol 2010; 149:278-283
21. Karpecki P, Depaolis M, Hunter JA, White EM, Rigel L, Brunner LS, Usner DW, Paterno MR, Comstock TL. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009; 31:514-526
22. Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009; 25:1159-1169
23. McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009; 116:1615-1623
24. Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009; 53:3552-3560. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715578/ pdf/0418-09.pdf. Accessed February 5, 2011
25. Carter NJ, Scott LJ. Besifloxacin ophthalmic suspension 0.6%. Drugs 2010; 70:83-97
26. Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 2010; 65:1441-1447. Available at: http://jac.oxfordjournals.org/content/65/7/1441.full.pdf. Accessed February 5, 2011
27. Bowman LM, Si E, Pang J, Archibald R, Friedlaender M. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocul Pharmacol Ther 2009; 25:133-139
28. Blondeau JM, Borsos S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother 2007; 19:146-151 (Pubitemid 46697733)
29. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999; 12:147-179. erratum 2001; 14:227. Available at: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC88911/pdf/cm000147. pdf. Erratum available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC88971/. Accessed February 5, 2011
30. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmcol Ther 2009; 25:335-343
31. Torkildsen G, Proksch JW, Shapiro A, Lynch SK, Comstock TL. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin Ophthalmol 2010; 4:331-341. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861941/ pdf/opth-4-331.pdf. Accessed February 5, 2011
32. Holland EJ, Lane SS, Kim T, Raizman M, Dunn S. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea 2008; 27:314-319 (Pubitemid 351440866)
33. Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, Pang CP. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol 2007; 144:315-318 (Pubitemid 47094713)
34. Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery. J Cataract Refract Surg 2008; 34:819-822 (Pubitemid 351626964)
35. McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006; 113:955-959 (Pubitemid 43795230)
36. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Thomas MA, Mieler WF, Chi J, Prince RA. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005; 123:39-44. Available at: http://archopht.ama-assn.org/cgi/reprint/123/1/39.pdf. Accessed February 5, 2011 (Pubitemid 40105427)
37. Katz HR, Masket S, Lane SS, Sall K, Orr SC, Faulkner RD, McCue BA, Dahlin DC. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005; 24:955-958 (Pubitemid 41688529)
38. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patents. Ophthalmology 2005; 112:1992-1996 (Pubitemid 41551929)
39. Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, Bloom A. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005; 112:466-469 (Pubitemid 40312502)
40. Holland EJ, McCarthy M, Holland S. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr Med Res Opin 2007; 23:2955-2960
41. Teshigawara T, Hata S, Hayashi T, Watanabe T, Itoh Y, Hitoi K, Mizuki N. Penetration of gatifloxacin eye drops into the aqueous humor in humans. Ocul Immunol Inflamm 2007; 15:309-313 (Pubitemid 47347036)
42. Yoshida J, Kim A, Pratzer KA, Stark WJ. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. J Cataract Refract Surg 2010; 36:1499-1502
43. Wright DH, Brown GH, Perterson ML, Rotshafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46:669-683. Available at: http://jac.oxfordjournals.org/content/46/5/669.full.pdf. Accessed February 5, 2011
44. Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents 2004; 24:150-160
45. Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004; 24:161-167 (Pubitemid 38993695)
46. Almeida DR, Miller D, Alfonso EC. Anterior chamber and vitreous concordance in endophthalmitis; implications for prophylaxis. Arch Ophthalmol 2010; 128:1136-1139
47. Proksch JW, Ward KW. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. J Ocul Pharmacol Ther 2010; 26:449-458
48. Sundelin K, Seal D, Gardner S, Ropo A, Geldsetzer K, Lokkila J, Stenevi U. Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients. Acta Ophthalmol 2009; 87:160-165. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2008.01358.x/pdf. Accessed February 5, 2011
49. Hesje CK, Borsos SD, Blondeau JM. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains. J Ocul Pharmacol Ther 2009; 25:329-334